BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1698020)

  • 21. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
    Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis.
    Arbo MD; Snydman DR; Wong JB; Goldberg HS; Schmid CH; Pauker SG
    Clin Transplant; 2000 Feb; 14(1):19-27. PubMed ID: 10693631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
    Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
    Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
    Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
    Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
    Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
    Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients.
    Wong T; Lavaud S; Toupance O; Carquin J; Wynckel A; Melin JP; Hanrotel C; Chanard J
    Transpl Int; 1993; 6(5):285-9. PubMed ID: 8216706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis.
    Tsevat J; Snydman DR; Pauker SG; Durand-Zaleski I; Werner BG; Levey AS
    Transplantation; 1991 Aug; 52(2):259-65. PubMed ID: 1651575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
    Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
    Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus infections in heart and heart-lung transplant recipients.
    Wreghitt T
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in cytomegalovirus prevention and management.
    Snydman DR; Rubin RH; Werner BG
    Am J Kidney Dis; 1993 Feb; 21(2):217-28. PubMed ID: 8381578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients.
    Avery RK
    Curr Opin Cardiol; 1998 Mar; 13(2):122-9. PubMed ID: 9593552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.